Soluble ADAMTSL2 proved to be a good biomarker to identify significant and advanced fibrosis in patients with NAFLD, while circulating TREM2 levels have proved to stratify patients with NASH9,17. Here, ADAMTSL2 is linked to metabolic dysfunction-associated steatotic liver disease.